Metagenomi(MGX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results Presented three abstracts at American Society of Gene & Cell Therapy ("ASGCT") demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $205.0 million in cash, cash equivalents and available-for-sale marketable securities as of June 30, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) – Metagenomi, Inc. (Nas ...